CAT
Caterpillar Inc.
CAT has a slight edge over SRTA overall, supported by stronger modeled upside and lower modeled downside.
SRTA
Strata Critical Medical, Inc.
SRTA offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
CAT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
CAT's revenue, profitability, cash flow and balance sheet are all currently healthy.
SRTA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Stable | |
| Strong |
SRTA's revenue and balance sheet are currently healthy, and its cash flow is stable, but its profitability is under pressure.
CAT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $380 | -37% |
| Fair | 18x | $461 | -24% |
| Forward | 20x | $605 | — |
| Current | 24x | $605 | — |
| Expensive | 33x | $840 | +39% |
Historical ranges are pointers, not guarantees.
CAT's PE is in its expensive range at 24x. If earnings grow as analysts expect, today's price would be 20x next year's earnings, in its fair range.
SRTA PE Valuation
SRTA has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 100x next year's earnings.
CAT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Moderate | |
| Low |
Analysts expect earnings and revenue growth for CAT, with profitability improving. However, they disagree widely on these estimates.
SRTA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect SRTA to return to profit, with revenue growing.
CAT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $30.32 | +19% |
| Q3 2026 | $25.48 | +31% |
| Q2 2026 | $23.23 | +18% |
| Q1 2026 | $20.08 | -2% |
| Q4 2025 | $18.81 | -15% |
| Q3 2025 | $19.46 | -9.7% |
| Q2 2025 | $19.64 | -10% |
| Q1 2025 | $20.50 | -7.4% |
| Q4 2024 | $22.05 | +9.6% |
CAT has the edge over SRTA on earnings quality, reporting a profit while its opponent remains loss making.
SRTA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.06 | — |
| Q3 2026 | -$0.29 | -158% |
| Q2 2026 | $0.50 | +$0.73 |
| Q1 2026 | $0.57 | +$0.90 |
| Q4 2025 | $0.50 | +$0.85 |
| Q3 2025 | $0.50 | +$1.19 |
| Q2 2025 | -$0.23 | +$0.43 |
| Q1 2025 | -$0.33 | +$0.35 |
| Q4 2024 | -$0.35 | +$0.41 |
SRTA has swung to a loss: it lost $0.29 per share over the past year, after a profit the year before.
CAT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.7B | +17% |
| Q2 2026 | $20.5B | +24% |
| Q1 2026 | $17.4B | +22% |
| Q4 2025 | $19.1B | +18% |
| Q3 2025 | $17.6B | +9.5% |
| Q2 2025 | $16.6B | -0.7% |
| Q1 2025 | $14.2B | -9.8% |
| Q4 2024 | $16.2B | -5% |
CAT's revenue has grown year over year for five quarters in a row: $20.7B last quarter, up 17% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +3.1 points |
| Q2 2026 | 21% | +3.6 points |
| Q1 2026 | 18% | -0.4 points |
| Q4 2025 | 14% | -4.1 points |
| Q3 2025 | 17% | -2.2 points |
| Q2 2025 | 17% | -3.6 points |
| Q1 2025 | 18% | -4.2 points |
| Q4 2024 | 18% | -0.3 points |
CAT has the edge over SRTA on profitability, with a higher operating margin.
SRTA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $74.1M | +50% |
| Q2 2026 | $72.5M | +2.4% |
| Q1 2026 | $67.4M | +24% |
| Q4 2025 | $66.8M | +23% |
| Q3 2025 | $49.3M | -34% |
| Q2 2025 | $70.8M | +4.2% |
| Q1 2025 | $54.3M | +5.4% |
| Q4 2024 | $54.4M | +14% |
SRTA's revenue has grown year over year for four quarters in a row: $74M last quarter, up 50% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -5.2% | +6.2 points |
| Q2 2026 | -7.5% | -0.5 points |
| Q1 2026 | -4.4% | +9.6 points |
| Q4 2025 | -9.6% | +5.8 points |
| Q3 2025 | -11% | -6.7 points |
| Q2 2025 | -7% | +11 points |
| Q1 2025 | -14% | +5.2 points |
| Q4 2024 | -15% | +60 points |
SRTA's operating margin was −5.2% last quarter, up 6.2 points from the same quarter a year ago.
CAT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +19% |
| Q2 2026 | $3.8B | +47% |
| Q1 2026 | $1.1B | +97% |
| Q4 2025 | $2.7B | +0.1% |
| Q3 2025 | $3.1B | -1.5% |
| Q2 2025 | $2.6B | -4.2% |
| Q1 2025 | $579M | -63% |
| Q4 2024 | $2.7B | -22% |
CAT generated $11.3B in free cash flow over the past year, up 26% from the year before.
SRTA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $9.1M | +$49.2M |
| Q2 2026 | $3.2M | +$8.6M |
| Q1 2026 | -$1.3M | +$1.6M |
| Q4 2025 | -$10.2M | -$3.8M |
| Q3 2025 | -$40.1M | -$37.2M |
| Q2 2025 | -$5.4M | +$2.4M |
| Q1 2025 | -$2.9M | +$13.5M |
| Q4 2024 | -$6.3M | +$3M |
SRTA has the edge over CAT on cash flow, with more consistent year-over-year improvement.
CAT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -1.6M shares |
| 1 year | -2.1% | -9.9M shares |
| 3 years | -10% | -51.7M shares |
| 5 years | -16% | -86.7M shares |
| Available history | -19% | -107M shares |
CAT has the edge over SRTA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.2B |
| Q2 2026 | $1.5B |
| Q1 2026 | $5B |
| Q4 2025 | $340M |
| Q3 2025 | $362M |
| Q2 2025 | $828M |
| Q1 2025 | $3.7B |
| Q4 2024 | $640M |
CAT spent $8.1B buying back its own shares over the past year, up 47% from the year before.
SRTA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.4% | +2.1M shares |
| 1 year | +7.1% | +5.8M shares |
| 3 years | +9% | +7.3M shares |
| 5 years | +71% | +36.7M shares |
| Available history | +977% | +80.1M shares |
SRTA has 88M diluted shares, up 7.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q4 2019 | — |
CAT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | 2.0x | Healthy |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.3x | Net Cash |
| Q4 2024 | 1.6x | Healthy |
CAT has more cash than debt.
SRTA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -10.7x | Net Cash |
SRTA has the edge over CAT on leverage, with a lower net debt burden relative to earnings.
CAT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.7 | Neutral |
| Stochastic | 6.7 | Oversold |
CAT's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
SRTA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.4 | Neutral |
| Stochastic | 49.4 | Neutral |
SRTA's weekly RSI is 57 (neutral) and its Stochastic is 49 (neutral).
CAT PE vs Industrials Sector
| Metric | CAT | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 24x | 1.3% below |
| PE % | 69 | 58 | 11 pts above |
CAT is trading at 24x earnings, in line with the Industrials sector's median of 24x.
SRTA PE vs Industrials Sector
| Metric | SRTA | Sector median | Relative |
|---|---|---|---|
| PE | 8.9x | 24x | 63% below |
| PE % | 20 | 58 | 38 pts below |
SRTA has the edge over CAT on valuation relative to its sector.
CAT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $709.0 | 15% below |
| 20 week MA | $797.0 | 24% below |
| 50 week MA | $771.3 | 22% below |
| 100 week MA | $586.7 | 3.2% above |
| 200 week MA | $443.1 | 37% above |
CAT has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 37% above its 200-week average.
SRTA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.95 | 17% above |
| 20 week MA | $5.25 | 9.9% above |
| 50 week MA | $5.11 | 13% above |
| 100 week MA | $4.53 | 27% above |
| 200 week MA | $3.94 | 46% above |
SRTA has the edge over CAT on trend strength, trading above more of its moving averages.
CAT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $148.3 | $179.6 | +21% |
| 2021 | $179.6 | $206.2 | +15% |
| 2022 | $206.2 | $239.9 | +16% |
| 2023 | $239.9 | $295.7 | +23% |
| 2024 | $295.7 | $364.9 | +23% |
| 2025 | $364.9 | $583.0 | +60% |
| 2026 YTD | $583.0 | $605.3 | +3.8% |
CAT has finished every year since 2020 higher, and it's up 3.8% so far in 2026.
SRTA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.83 | $11.0 | +12% |
| 2021 | $11.0 | $9.25 | -16% |
| 2022 | $9.25 | $3.50 | -62% |
| 2023 | $3.50 | $3.53 | +0.9% |
| 2024 | $3.53 | $4.41 | +25% |
| 2025 | $4.41 | $4.87 | +10% |
| 2026 YTD | $4.87 | $5.77 | +18% |
SRTA has the edge over CAT on returns for 2026, with the stronger performance.